BioNTech Finalizes Acquisition of InstaDeep for $549M
AI, ML-based deal builds on the parties’ existing relationship.
BioNTech has officially completed the acquisition of InstaDeep Ltd.—a technology company in the artificial intelligence (AI) and machine learning (ML) space—for approximately $549 million. Although this deal was originally announced this past January, the news actually follows a history of collaboration between the two parties since 2019; it is important to note that BioNTech also provided an initial equity investment as part of InstaDeep’s Series B financing round in January 2022.
The acquisition supports BioNTech’s strategy of aiming to build capabilities in AI-driven drug discovery and development of immunotherapies and vaccines to address diseases with high unmet medical need. InstaDeep will operate as a UK-based global subsidiary of BioNTech.
In addition to BioNTech-focused projects, InstaDeep will continue to provide its services to clients in other industries, including in the technology and transport & logistics sectors. The transaction adds approximately 290 highly skilled professionals to BioNTech’s workforce, including teams in AI, ML, bioengineering, data science, and software development.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
